MA41794A - Agents thérapeutiques modifiés et compositions associées - Google Patents

Agents thérapeutiques modifiés et compositions associées

Info

Publication number
MA41794A
MA41794A MA041794A MA41794A MA41794A MA 41794 A MA41794 A MA 41794A MA 041794 A MA041794 A MA 041794A MA 41794 A MA41794 A MA 41794A MA 41794 A MA41794 A MA 41794A
Authority
MA
Morocco
Prior art keywords
therapeutic agents
modified therapeutic
associated compositions
compositions
modified
Prior art date
Application number
MA041794A
Other languages
English (en)
Inventor
Avinash Muppidi
Peter G Schultz
Weijun Shen
Original Assignee
The California Institute For Biomedical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The California Institute For Biomedical Res filed Critical The California Institute For Biomedical Res
Publication of MA41794A publication Critical patent/MA41794A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MA041794A 2015-03-18 2016-03-16 Agents thérapeutiques modifiés et compositions associées MA41794A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562134939P 2015-03-18 2015-03-18

Publications (1)

Publication Number Publication Date
MA41794A true MA41794A (fr) 2018-01-23

Family

ID=56919638

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041794A MA41794A (fr) 2015-03-18 2016-03-16 Agents thérapeutiques modifiés et compositions associées

Country Status (9)

Country Link
US (1) US20180207276A1 (fr)
EP (1) EP3270946A2 (fr)
JP (1) JP2018511574A (fr)
KR (1) KR20170125978A (fr)
CN (1) CN107645955A (fr)
AU (1) AU2016233128A1 (fr)
CA (1) CA2978184A1 (fr)
MA (1) MA41794A (fr)
WO (1) WO2016149501A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015038938A1 (fr) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Agents thérapeutiques modifiés et compositions de ceux-ci
US10039809B2 (en) 2013-12-18 2018-08-07 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
EP3310376A4 (fr) * 2015-06-17 2019-01-23 The California Institute for Biomedical Research Agents thérapeutiques modifiés et compositions associées
KR102433503B1 (ko) 2016-05-24 2022-08-18 노보 노르디스크 에이/에스 Mic-1 화합물 및 이것의 사용
SG10201912034UA (en) 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
CA3057292A1 (fr) * 2017-03-22 2018-09-27 The Regents Of The University Of California Oligonucleotides modifies et leurs utilisations therapeutiques
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
WO2019085773A1 (fr) * 2017-11-06 2019-05-09 中山大学 Polypeptide agoniste à double cible glp-1r/gcgr analogue d'oxyntomoduline pour le traitement de la fibrose interstitielle pulmonaire idiopathique
TW202027794A (zh) * 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
EP3819307A1 (fr) 2019-11-07 2021-05-12 CytoKi Pharma ApS Dérivés thérapeutiques de l'interleukine-22
KR102193211B1 (ko) * 2019-11-27 2020-12-18 (주)디앤디파마텍 비오틴 모이어티가 결합된 폴리펩티드 및 이를 포함하는 경구 투여용 약학적 조성물
EP4069726A4 (fr) 2019-12-04 2024-03-20 The Scripps Research Institute Agonistes du récepteur glp2 et méthodes d'utilisation
JP7663882B6 (ja) * 2020-01-20 2025-06-10 ルダキュア コーポレーション Ｔｒｐｖ１活性媒介疾患治療用の薬学的組成物
CN114478709A (zh) * 2020-11-13 2022-05-13 成都奥达生物科技有限公司 一种长效肝炎病毒进入抑制剂
US20240279297A1 (en) * 2021-05-11 2024-08-22 Cytoki Pharma Aps Therapeutic derivatives of interleukin-22
AU2022289610A1 (en) 2021-06-09 2024-01-25 The Scripps Research Institute Long-acting dual gip/glp-1 peptide conjugates and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5911997A (en) * 1995-06-07 1999-06-15 Connetics Corporation Relaxin-like factor and methods and uses thereof
PE20140160A1 (es) * 2010-08-17 2014-02-08 Ambrx Inc Polipeptidos de relaxina modificados y sus usos
AU2012283235A1 (en) * 2011-07-08 2014-01-09 Bayer Intellectual Property Gmbh Fusion proteins releasing Relaxin and uses thereof

Also Published As

Publication number Publication date
JP2018511574A (ja) 2018-04-26
EP3270946A2 (fr) 2018-01-24
WO2016149501A3 (fr) 2016-11-24
US20180207276A1 (en) 2018-07-26
KR20170125978A (ko) 2017-11-15
WO2016149501A2 (fr) 2016-09-22
CA2978184A1 (fr) 2016-09-22
CN107645955A (zh) 2018-01-30
AU2016233128A1 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
IL258931A (en) Therapeutic compounds and methods
IL259795A (en) Methods and compositions for treating a serpinc1-associated disorder
EP3310376A4 (fr) Agents thérapeutiques modifiés et compositions associées
EP3474820C0 (fr) Compositions glp-1 et ses utilisations
EP3513809A4 (fr) Composition médicinale
KR20180084891A (ko) 구조 조성물 및 방법
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
PL3265448T3 (pl) Proleki riluzolu i ich zastosowanie
EP3291824C0 (fr) Thérapie antimicrobienne
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
MA40764A (fr) Agent thérapeutique induisant une cytotoxicité
DK3107563T3 (da) Glycomålrettede terapeutiske midler
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
LT3426226T (lt) Oftalmologinė kompozicija
DK3102200T3 (da) Terapeutisk forbindelse og sammensætning
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
IL255307B (en) Tpp1 formulations and uses thereon in cln2 disease
IL258997B (en) Honey-cannabinoid therapeutic composition
DK3194564T3 (da) Trichodermasammensætninger og anvendelsesfremgangsmåder
EP3436467A4 (fr) Nouvelles compositions et méthodes thérapeutiques
PT3261437T (pt) Compostos e composições fungicidas
DK3408265T3 (da) Terapeutiske forbindelser
EP3362091A4 (fr) Polythérapie
IL262851A (en) Combination prime: boost therapy
DK3393478T3 (da) Kombinationsterapi